skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Preparation, characterization, and in vitro release study of albendazole-encapsulated nanosize liposomes

Original Research

(2715) Views  (913) Full article downloads

Authors: Preety Panwar, Bhumika Pandey, P C Lakhera, et al

Published Date February 2010 Volume 2010:5 Pages 101 - 108
DOI: http://dx.doi.org/10.2147/IJN.S8030

Preety Panwar1, Bhumika Pandey1, P C Lakhera2, K P Singh1

1Biophysics and Nanotechnology Research Laboratory, CBSH, G.B. Pant University of Agriculture and Technology, Pantnagar, Uttarakhand, India; 2Department of Biotechnology, H.N.B. Garhwal University, Srinagar Garhwal, Uttarakhand, India

Abstract: The purpose of the present study was to formulate effective and controlled release albendazole liposomal formulations. Albendazole, a hydrophobic drug used for the treatment of hydatid cysts, was encapsulated in nanosize liposomes. Rapid evaporation method was used for the preparation of albendazole-encapsulated conventional and PEGylated liposomes consisting of egg phosphatidylcholine (PC) and cholesterol (CH) in the molar ratios of (6:4) and PC:CH:polyethylene glycol (PEG) (5:4:1), respectively. In this study, PEGylated and conventional liposomes containing albendazole were prepared and their characteristics, such as particle size, encapsulation efficiency, and in vitro drug release were investigated. The drug encapsulation efficiency of PEGylated and conventional liposomes was 81% and 72%, respectively. The biophysical characterization of both conventional and PEG-coated liposomes were done by transmission electron microscopy and UV-vis spectrophotometry. Efforts were made to study in vitro release of albendazole. The drug release rate showed decrease in albendazole release in descending order: free albendazole, albendazole-loaded conventional liposomes, and least with albendazole-loaded PEG-liposomes. Biologically relevant vesicles were prepared and in vitro release of liposome-entrapped albendazole was determined.

Keywords: albendazole, PEGylated, in vitro release, liposomes, nanosize








Readers of this article also read:

Evidence-based decision-making within the context of globalization: A “Why–What–How” for leaders and managers of health care organizations
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
The pathophysiology of bronchiectasis
Overview of the main methods used to combine proteins with nanosystems: absorption, bioconjugation, and encapsulation
Antitumoral activity of L-ascorbic acid-poly-D,L-(lactide-co-glycolide) nanoparticles containing violacein
Magnetic nanoformulation of azidothymidine 5’-triphosphate for targeted delivery across the blood–brain barrier
Morgellons disease: Analysis of a population with clinically confirmed microscopic subcutaneous fibers of unknown etiology
Doxorubicin-loaded phosphatidylethanolamine-conjugated nanoliposomes: in vitro characterization and their accumulation in liver, kidneys, and lungs in rats
Radio electric asymmetric brain stimulation in the treatment of behavioral and psychiatric symptoms in Alzheimer disease
Elucidation mechanism of different biological responses to multi-walled carbon nanotubes using four cell lines